Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $54.22M |
| Net Income (Most Recent Fiscal Year) | $-57.89M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -165.21% |
| Net Margin (Trailing 12 Months) | -165.22% |
| Return on Equity (Trailing 12 Months) | -459.57% |
| Return on Assets (Trailing 12 Months) | -57.71% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.19 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 4.01 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 26.69M |
| Free Float | 20.79M |
| Market Capitalization | $54.45M |
| Average Volume (Last 20 Days) | 0.17M |
| Beta (Past 60 Months) | 0.75 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 19.02% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |